MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
1.780
-0.015
-0.84%
After Hours: 1.779 -0.001 -0.04% 19:55 05/14 EDT
OPEN
1.820
PREV CLOSE
1.795
HIGH
1.898
LOW
1.750
VOLUME
2.75M
TURNOVER
--
52 WEEK HIGH
9.49
52 WEEK LOW
1.260
MARKET CAP
401.49M
P/E (TTM)
-2.0124
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: Sana Biotechnology (SANA), Tyra Bioscience (TYRA)
TipRanks · 16h ago
SANA Lawsuit Alert! Class Action Lawsuit Against Sana Biotechnology, Inc.
TipRanks · 19h ago
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Barchart · 1d ago
Sana Biotechnology Reports Improved Quarterly Loss
TipRanks · 1d ago
Weekly Report: what happened at SANA last week (0505-0509)?
Weekly Report · 2d ago
Bank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)
TipRanks · 5d ago
Buy Rating for Sana Biotechnology Driven by Promising Clinical Data and Strategic Advancements
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Tyra Bioscience (TYRA)
TipRanks · 6d ago
More
About SANA
More
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Recently
Symbol
Price
%Change

Webull offers Sana Biotechnology Inc stock information, including NASDAQ: SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.